PubMed Health⌕ Search

PubMed · 8790095

Proliferative radiation retinopathy.

Abstract

OBJECTIVES: To compare proliferative radiation retinopathy (PRR) with nonproliferative radiation retinopathy (NPRR) and to assess the outcome of panretinal photocoagulation treatment for PRR. METHODS: We reviewed the medical records, fundus photographs, and fluorescein angiograms of 10 patients (14 eyes) with PRR, which was diagnosed in a tertiary referral center during a 20-year period. The collected data included the following: the indications for radiation treatment, radiotherapy technique used, dose and fractions of radiation, visual acuity, indications for photocoagulation treatment, photocoagulation technique used, and response to treatment. Comparisons were made with data from 17 patients (27 eyes) with NPRR, which had not progressed to PRR during the course of this study. RESULTS: The initial visual acuity of the 14 eyes with PRR ranged from 20/20 to hand motion; these eyes had a median visual acuity of 20/90. The initial visual acuity of the 27 eyes with NPRR ranged from 20/15 to 20/400; these eyes had a median visual acuity of 20/25. Five (36%) of the eyes with PRR and 4 (15%) of the eyes with NPRR (P = .35) had a visual acuity of 20/200 or worse. After a mean follow-up time of 75 months for the eyes with PRR and 51 months for the eyes with NPRR, the median visual acuities were 20/400 and 20/50, respectively; 12 (86%) of the 14 eyes with PRR had a visual acuity of 20/200 or worse vs 7 (26%) of the 27 eyes with NPRR (P < .007). The new vessels had resolved in 10 (91%) of the 11 eyes that were treated with panretinal photocoagulation for PRR. CONCLUSIONS: Eyes with PRR have a poor prognosis for retaining and regaining good central vision. Panretinal photocoagulation seems to have long-term effectiveness in decreasing the proliferation of new vessels due to complications of radiation treatment.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J L Kinyoun, B S Lawrence, W E Barlow. 1996. Proliferative radiation retinopathy.. https://doi.org/10.1001/archopht.1996.01100140299007

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Radiotherapy for orbital lymphoma : outcome and late effects.

PURPOSE: To analyze the effectiveness of radiotherapy in the management of orbital non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: 42 patients (median age 64.5 years) were reviewed retrospectively. The median follow-up period was 58 months. 26 patients had stage IE orbital lymphoma (22 indolent, four aggressive NHLs). 16 patients had advanced NHLs in stages II-IV with orbital involvement (eleven indolent, five aggressive NHLs). The median radiation dose was 40 Gy (20-46 Gy) for indolent lymphoma and 44 Gy (20-48 Gy) for aggressive lymphoma. Patients with stage IE were treated with at least 30 Gy. RESULTS: The 5-year local control rate for patients with stage I was 100%, the 5-year overall survival 91%. Two distant relapses were found, but no lymphoma-related death was detected. The 5-year local control rate for patients in stages II, III, and IV was 80%. Two local failures were detected. The 5-year overall survival for the advanced stages was 47%, nine patients with stages III and IV died due to systemic progression of lymphoma. Acute, radiotherapy-related complications grade 3/4 were not observed. Late effects grade 1/2 were documented in 45%. Six patients, treated with doses of > 36 Gy, developed grade 3 complications (four cataract, two dryness). CONCLUSION: Radiotherapy alone yields excellent local control and overall survival rates in orbital lymphoma stage IE. Local irradiation is also well tolerated and effective in advanced NHL stages with orbital infiltration. Doses of > 36 Gy resulted in an increase of late complications.

Eye Neoplasms↗

Optometrists as key providers in the prevention and early detection of malignancies.

Optometrists have become active in many aspects of primary health care. Opportunities exist for optometrists to join other health care providers in the fight against cancer. The purpose of this article is to review information about cancer epidemiology, describe cancer screening guidelines, and to provide examples of ways for optometrists to become involved in promoting goals for reducing cancer risk and increasing the early detection of cancer. In addition to diagnosing ocular cancers and metastases to the eye and orbital region, optometrists may provide cancer information as part of their case history, provide positive health messages to reduce cancer risk factors, and directly observe signs of skin cancer.

Eye Neoplasms↗

[Immunohistochemistry in ophthalmic pathology: applications and limitations].

We evaluate the applications of immunohistochemistry (IHC) in ophthalmic cytology and pathology. The principles of the techniques used in IHC are described. Recent improvements are highlighted, such as the polymeric labeling two-step method, tyramine signal amplification, rabbit monoclonal antibodies, and labeled nanocrystals. The results of the immunohistochemical methods are collected in bacterial and viral diseases and in tumors of the eye and its adnexa, the pathology of which varies greatly. The results in lymphomas, melanomas, and palpebral tumors were more details for practical reasons. There are widespread applications of IHC in ophthalmic pathology, extending from viral ocular and general diseases to the diagnosis of tumors. In some conditions, this technique needs to be associated with molecular biology investigations. Automation helps establish standard protocols, but IHC is a multistep diagnostic method requiring proper selection, fixation, processing, and staining procedures. From a general standpoint, good communication between pathologists and ophthalmologists is the best guarantee of satisfying results.

Eye Neoplasms↗